# Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines

> **NCT05875701** · PHASE3 · COMPLETED · sponsor: **Novavax** · enrollment: 147 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** NVX-CoV2373
- **BIOLOGICAL:** SARS-CoV-2 rS antigen/Matrix-M Adjuvant

## Key facts

- **NCT ID:** NCT05875701
- **Lead sponsor:** Novavax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-28
- **Primary completion:** 2023-11-11
- **Final completion:** 2023-11-11
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05875701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05875701, "Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05875701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*